FHD 286
Alternative Names: FHD-286Latest Information Update: 23 Dec 2024
At a glance
- Originator Foghorn Therapeutics
- Class Amides; Amines; Antineoplastics; Morpholines; Pyridines; Pyrroles; Small molecules; Thiazoles
- Mechanism of Action SMARCA2 protein inhibitors; SMARCA4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Acute myeloid leukaemia; Myelodysplastic syndromes
- Discontinued Non-small cell lung cancer; Uveal melanoma
Most Recent Events
- 23 Dec 2024 Discontinued - Preclinical for Non-small cell lung cancer in USA (PO)
- 23 Dec 2024 Suspended - Phase-I for Acute myeloid leukaemia (Combination therapy, In adolescents, In the elderly, Second-line therapy or greater, In adults) in USA (PO)
- 23 Dec 2024 Suspended - Phase-I for Myelodysplastic syndromes (Late-stage disease, Monotherapy, Second-line therapy or greater) in USA (PO)